Photo by Myriam Zilles on Unsplash
The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products.
Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to make its selections.
The organization will announce the final competition winners at a ceremony in New York City on Oct. 28, 2021.
[Related: The most innovative pharmaceutical agents of 2020]
In terms of pharmaceutical agents, the organization selected the following 34 nominees:
Company |
Drug name |
|
Rinvoq (upadacitinib) |
|
|
Adlon Therapeutics L.P., a subsidiary of Purdue Pharma |
Adhansia XR (methylphenidate HCI) |
|
Advanced Accelerator Applications USA, Inc., a Novartis company |
Lutathera (lutetium Lu 177 dotatate) |
|
Xospata (gilteritinib) |
|
|
Nubeqa (darolutamide) |
|
|
Vitrakvi (larotrectinib) |
|
|
Biohaven Pharmaceuticals |
Nurtec ODT (rimegepant) |
|
Blueprint Medicines |
Ayvakit (avapritinib) |
|
Blueprint Medicines |
Gavreto (pralsetinib) |
|
Deciphera Pharmaceuticals |
Qinlock (ripretinib) |
|
Eiger BioPharmaceuticals, Inc. |
Zokinvy (lonafarnib) |
|
Olumiant (baricitinib) |
|
|
Reyvow (lasmiditan) |
|
|
Epizyme Inc. |
Tazverik (tazemetostat) |
|
Esperion Therapeutics Inc. |
Nexlizet (bempedoic acid and ezetimibe) |
|
Esperion Therapeutics Inc. |
Nexletol (bempedoic acid) |
|
Genentech, a member of the Roche Group |
Rozlytrek (entrectinib) |
|
Veklury (remdesivir) |
|
|
Pemazyre (pemigatinib) |
|
|
Karyopharm Therapeutics Inc. |
Xpovio (selinexor) |
|
Medicines Development for Global Health |
|
|
Recarbrio (imipenem, cilastatin and relebactam) |
|
|
Myovant Sciences, Inc. |
Orgovyx (relugolix) |
|
Adakveo (crizanlizumab) |
|
|
Entresto (sacubitril/valsartan) |
|
|
Piqray (alpelisib) |
|
|
Braftovi Mektovi (encorafenib/binimetinib) |
|
|
Lorbrena (lorlatinib) |
|
|
Population Council |
Annovera (segesterone acetate and ethinyl estradiol) |
|
Seagen |
Tukysa (tucatinib) |
|
Servier Pharmaceuticals |
Asparlas (calaspargase pegol-mknl injection) |
|
SIGA Technologies, Inc. |
Tpoxx (tecovirimat) |
|
Sobi, Inc. |
Gamifant (emapalumab-lzsg) |
|
Elyxyb (celecoxib) |
Filed Under: Cardiovascular, Dermatology, Drug Discovery, Infectious Disease, Neurological Disease, Oncology, Rheumatology
